Notice of Intent to Publish a Funding Opportunity Announcement to Support Biofabricated 3D Tissue Models of Nociception, Opioid Use Disorder and Overdose for Drug Screening (UH2/UH3 – Clinical Trial Not Allowed)

0
261

Opportunity ID: 310194
Opportunity Number: NOT-TR-19-006
Opportunity Title: Notice of Intent to Publish a Funding Opportunity Announcement to Support Biofabricated 3D Tissue Models of Nociception, Opioid Use Disorder and Overdose for Drug Screening (UH2/UH3 – Clinical Trial Not Allowed)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Health
Category Explanation:
CFDA Number(s): 93.350
Eligible Applicants: State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility:
Agency Code: HHS-NIH11
Agency Name: Department of Health and Human Services
National Institutes of Health
Posted Date: Nov 05, 2018
Last Updated Date: Nov 05, 2018
Estimated Synopsis Post Date: Dec 01, 2018
Fiscal Year: 2019
Award Ceiling:
Award Floor:
Estimated Total Program Funding: $1,500,000
Expected Number of Awards: 2
Description: The National Center for Advancing Translational Sciences (NCATS), as part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative, intends to publish a Funding Opportunity Announcement (FOA) to speed scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative will bolster research across NIH to (1) improve treatment for opioid misuse and addiction and (2) enhance pain management. More information about the HEAL Initiative is available at: https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative The FOA will utilize the UH2/UH3 activity code and is expected to be published in December 2018 with an application due date in February 2019. The FOA will invite applications to develop and implement the use of 3D biofabricated tissue models in novel drug screening platforms, and advance pre-clinical discovery and development of non-addictive treatments for nociception, opioid use disorder (OUD) and/or overdose. In particular, during the UH2 phase this FOA supports the application of 3D biofabrication technologies to develop novel multicellular tissue constructs for drug screening by using physiologically-relevant human cells representing sensory/pain neurons, brain regions, and other tissues involved in nociception, addiction and/or overdose, including tissue models of the blood-brain barrier (BBB). The goal of the UH3 phase is to develop a screening platform and identify compounds that modulate the relevant phenotypes for pain, opioid use disorder and/or overdose. This FOA is looking for collaborations that can leverage both the NCATS 3D Bioprinting Laboratory’s biofabrication and screening capabilities (https://ncats.nih.gov/bioprinting) with the pain expertise and cell resources of the extramural research community. This Notice is being provided to allow potential applicants sufficient time to develop responsive proposals, consider the requirements that are integral to this initiative, and establish appropriate collaborations.
Version: 1





Visit the Official Webpage For More Details on Notice of Intent to Publish a Funding Opportunity Announcement to Support Biofabricated 3D Tissue Models of Nociception, Opioid Use Disorder and Overdose for Drug Screening (UH2/UH3 – Clinical Trial Not Allowed)